The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a huge mover today! About 3.16 million shares traded hands or 73.63% up from the average. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 44.97% since April 4, 2016 and is downtrending. It has underperformed by 46.06% the S&P500.
The move comes after 9 months positive chart setup for the $624.10 million company. It was reported on Nov, 4 by Barchart.com. We have $6.38 PT which if reached, will make NASDAQ:ACHN worth $237.16 million more.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage
Out of 9 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. Achillion Pharma has been the topic of 15 analyst reports since August 13, 2015 according to StockzIntelligence Inc. Chardan Capital Markets upgraded Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Friday, November 4 to “Neutral” rating. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has “Buy” rating given on Thursday, February 25 by Maxim Group. UBS upgraded Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Tuesday, September 8 to “Buy” rating. On Thursday, August 13 the stock rating was maintained by Maxim Group with “Buy”. The company was initiated on Thursday, July 14 by Chardan Capital Markets. The stock has “Outperform” rating given by Wedbush on Friday, September 23. The company was upgraded on Thursday, July 7 by JMP Securities. The company was upgraded on Friday, February 26 by Robert W. Baird. The firm has “Outperform” rating given on Thursday, September 15 by FBR Capital. The rating was maintained by Chardan Capital Markets with “Sell” on Friday, September 23.
According to Zacks Investment Research, “ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company’s proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.08, from 0.92 in 2016Q1. The ratio improved, as 21 funds sold all Achillion Pharmaceuticals, Inc. shares owned while 39 reduced positions. 12 funds bought stakes while 48 increased positions. They now own 107.31 million shares or 4.98% less from 112.94 million shares in 2016Q1.
Financial Bank Of America De has 500,417 shares for 0% of their US portfolio. Dekabank Deutsche Girozentrale, a Germany-based fund reported 70,300 shares. Doheny Asset Ca accumulated 105,850 shares or 0.41% of the stock. Rhenman & Asset Ab holds 0.37% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 266,000 shares. Amer Intll last reported 67,453 shares in the company. Goldman Sachs Grp holds 0.01% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 3.98M shares. American Century Cos Incorporated accumulated 0.01% or 870,293 shares. Dafna Capital Ltd Liability last reported 1.46% of its portfolio in the stock. Blackrock Mngmt Limited Liability Corporation holds 437,200 shares or 0% of its portfolio. Geode Capital Limited Liability Co reported 880,254 shares or 0% of all its holdings. Columbus Circle Investors last reported 0.01% of its portfolio in the stock. Rtw Invs Ltd Liability accumulated 6.46% or 2.42 million shares. Brave Asset Mgmt, a New Jersey-based fund reported 4,600 shares. Legal & General Public Limited, a United Kingdom-based fund reported 18,010 shares. Raymond James Associate last reported 0% of its portfolio in the stock.
ACHN Company Profile
Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Firm has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.